Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

With AJANTPHARM's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 2.638000
forwardPE 28.018263
debtToEquity 5.747000
earningsGrowth 0.186000
revenueGrowth 0.215000
grossMargins 0.782910
operatingMargins 0.231940
trailingEps 84.600000
forwardEps 113.890000

AJANTPHARM's current ratio of 2.638 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, AJANTPHARM can comfortably cover its liabilities, reflecting a strong financial outlook.
AJANTPHARM's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
AJANTPHARM's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning AJANTPHARM for continued success in the market.
With positive gross and operating margins, Ajanta Pharma Limited demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
Ajanta Pharma Limited's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that Ajanta Pharma Limited is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's price has continuously remained near the lower end of analysts' projections, indicating that it may be facing challenges in meeting market expectations. This trend raises concerns about the company's future growth trajectory.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


5 transactions to sell AJANTPHARM occurred, with market price at 2706.360009765625.During the review period, no sell transactions were executed.More recent purchases than sales at current price levels for Ajanta Pharma Limited could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts' buy bias toward AJANTPHARM suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, AJANTPHARM is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.